Asia-Pacific Pharmaceutical CMO Market Share Analysis, Trends And Growth Forecasts To 2030 Featuring Catalent, Recipharm, Jubilant Life Sciences And More

(MENAFN- GlobeNewsWire - Nasdaq) Key industry drivers include cost advantages in China, 100% FDI in India, and demand for injectable drugs in cancer research

Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Pharmaceutical Contract Manufacturing Organization - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025-2030)" report has been added to ResearchAndMarkets.com's offering.

The Asia-Pacific Pharmaceutical Contract Manufacturing Organization (CMO) Market is poised for remarkable growth, advancing from an estimated USD 59.97 billion in 2025 to a forecasted USD 91.18 billion by 2030, reflecting a robust compound annual growth rate (CAGR) of 8.74% during this period.

China's competitive edge in the CMO market is underscored by its low labor costs, tax incentives, and advantageous currency valuation, which enable pharmaceutical companies to significantly reduce manufacturing expenses. The country benefits from a workforce trained in Western standards, who are returning amid stringent immigration policies abroad. These dynamics, along with government support, have positioned China as a major pharmaceutical manufacturing hub.

• India, too, is capitalizing on the burgeoning CMO market, attracting Japanese pharmaceutical investments through favorable foreign direct investment policies. This strategic alignment is fostering partnerships that significantly bolster the domestic manufacturing landscape.
• Japan's CMO sector, although nascent, has observed a substantial 30% growth following regulatory changes that distinguish manufacturing from sales. Leading players include Bushu Pharmaceuticals and CMIC.
• Australia's pharmaceuticals face challenges due to pricing and reimbursement volatility, yet its geographical location near South Asian markets enhances its export potential.
• The COVID-19 pandemic, having originated in Wuhan, a vital pharmaceutical center, has affected global supply chains. This disruption necessitates strategic responses to inventory management, as China provides essential raw materials.

Injectable Dose Formulations Lead Growth

• The demand for injectable drugs, driven by the need for rapid acting oncology treatments, underscores a significant opportunity within the market. These formulations promise higher returns due to therapeutic efficiency and swift action.
• Prolific late-stage clinical trials, chiefly in cancer therapies, are poised to amplify market growth, with anti-cancer drugs comprising nearly half of the developmental pipeline.
• Outsourcing of biologic formulations to CMOs is prevalent, as major pharmaceutical entities concentrate on the discovery and development of new drug modalities.

India's Impactful CMO Market Share

• India leverages its vast manpower and regulatory approval to attract multinational pharmaceutical enterprises, enhancing its global footprint in drug manufacturing.
• Recent policies allowing certain drug studies without late-stage clinical trials lead to considerable cost savings, fortifying India's appeal for pharmaceutical production.
• The impact of the COVID-19 outbreak on India's sector is evident, with increased costs for APIs due to reliance on Chinese production.

The APAC pharmaceutical CMO market shows a highly fragmented landscape. Large pharmaceutical firms are increasingly outsourcing production to CMOs, seeking cost efficiency and expertise. Vendors are expanding through strategic collaborations to enhance market share. Recent industry developments include expansions by Jubilant Biosys in India and Boehringer's capacity increase in China.

Key Topics Covered
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Industry Attractiveness - Porter's Five Forces Analysis
4.3 Industry Value Chain Analysis
4.4 Industry Policies
4.5 Market Drivers
4.5.1 Increasing Outsourcing Volume by Pharmaceutical Companies
4.6 Market Restraints
4.6.1 Increasing Lead Time and Logistics Costs
4.6.2 Stringent Regulatory Requirements
4.6.3 Capacity Utilization Issues Affecting the Profitability of CMOs
4.7 Assessment of Impact of COVID-19 on the market
5 TECHNOLOGY SNAPSHOT
6 MARKET SEGMENTATION
6.1 Service Type
6.1.1 Active Pharmaceutical Ingredient (API) Manufacturing
6.1.1.1 Small Molecule
6.1.1.2 Large Molecule
6.1.1.3 High Potency API (HPAPI)
6.1.2 Finished Dosage Formulation (FDF) Development and Manufacturing
6.1.2.1 Solid Dose Formulation
6.1.2.2 Liquid Dose Formulation
6.1.2.3 Injectable Dose Formulation
6.1.3 Secondary Packaging
6.2 Country
6.2.1 China
6.2.2 India
6.2.3 Japan
6.2.4 Australia
6.2.5 Rest of Asia-Pacific
7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Catalent Inc.
7.1.2 Recipharm AB
7.1.3 Jubilant Life Sciences Ltd.
7.1.4 Thermo Fisher Scientific Inc. (Patheon Inc.)
7.1.5 Boehringer Ingelheim Group
7.1.6 Pfizer CentreSource (Pfizer Inc.)
7.1.7 Aenova Group
7.1.8 Famar SA
7.1.9 Baxter Biopharma Solutions(Baxter International Inc.)
7.1.10 Lonza Group
8 INVESTMENT ANALYSIS
9 FUTURE OF THE MARKET

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN06062025004107003653ID1109644514